New p32/gC1qR Ligands for Targeted Tumor Drug Delivery

ChemBioChem - Tập 17 Số 7 - Trang 570-575 - 2016
Lauri Paasonen1,2, Shweta Sharma1, Gary B. Braun1, Venkata Ramana Kotamraju3,1, Thomas D.Y. Chung4, Yugang Dong1, Kazuki N. Sugahara5,1, Marjo Yliperttula2, Bainan Wu1, Maurizio Pellecchia1,6, Erkki Ruoslahti3,1, Tambet Teesalu7,3,1
1Sanford Burnham Prebys Medical Discovery Institute, Cancer Research Center, 10901 North Torrey Pines Road, La Jolla, CA, 93027 USA
2University of Helsinki, Faculty of Pharmacy, Division of Pharmaceutical Biosciences, Viikinkaari 5E, Helsinki, 00014 Finland
3Sanford Burnham Prebys Medical Discovery Institute Center for Nanomedicine, University of California, Santa Barbara, Santa Barbara, CA, 93106 USA
4Sanford Burnham Prebys Medical Discovery Institute, Conrad Prebys Center for Chemical Genomics, 10901 North Torrey Pines Road, La Jolla, CA, 93027 USA
5Department of Surgery, Columbia University College of Physicians and Surgeons, 1130 St Nicholas Avenue, Suite 217C, New York, NY, 100032 USA
6School of Medicine, University of California Riverside, Riverside, CA 92521, USA
7Laboratory of Cancer Biology, Institute of Biomedicine and Translational Medicine, University of Tartu, Ravila 14B, Tartu, 50411 Estonia

Tóm tắt

AbstractCell surface p32, the target of LyP‐1 homing peptide, is upregulated in tumors and atherosclerotic plaques and has been widely used as a receptor for systemic delivery of payloads. Here, we identified an improved LyP‐1‐mimicking peptide (TT1, CKRGARSTC). We used this peptide in a fluorescence polarization‐based high‐throughput screening of a 50 000‐compound chemical library and identified a panel of compounds that bind p32 with low micromolar affinity. Among the hits identified in the screen, two compounds were shown to specifically bind to p32 in multiple assays. One of these compounds was chosen for an in vivo study. Nanoparticles surface‐functionalized with this compound specifically adhered to surfaces coated with recombinant p32 and, when injected intravenously, homed to p32‐expressing breast tumors in mice. This compound provides a lead for the development of p32‐targeted affinity ligands that circumvent some of the limitations of peptide‐based probes in guided drug delivery.

Từ khóa


Tài liệu tham khảo

10.1083/jcb.200910104

10.1038/nm720

10.1158/0008-5472.CAN-07-6752

10.1016/j.nano.2008.07.007

10.1073/pnas.0909565107

10.1016/j.ijpharm.2009.10.014

10.1016/j.jconrel.2011.07.034

10.1073/pnas.0403317101

10.1073/pnas.1104540108

10.1517/17425255.2011.574126

10.1002/anie.201205674

10.1002/ange.201205674

10.1021/jp9006119

10.1182/blood-2010-03-274258

10.1007/s10822-012-9623-5

10.1016/S1359-6446(00)01594-4

10.1158/0008-5472.CAN-07-6771

10.2174/13816128113199990375

10.1517/17425255.2.4.591

10.1177/108705710000500501

10.1517/17460441.2011.537322

10.1046/j.0014-2956.2001.02654.x

10.1073/pnas.0908201106

NIH PAR-14–284: High Throughput Screening HTS to Discover Chemical Probes.http://grants.nih.gov/grants/guide/pa-files/PAR-14-284.html 2014.

10.1177/108705719900400206

10.1016/B978-0-12-396962-0.00002-1

10.1021/cr500043b

10.1038/nmat3982

10.1002/smll.200801789

10.1038/mt.2013.191

10.1002/adma.201200454

10.1038/513481a

Fujimori K., 1990, J. Nucl. Med., 31, 1191

Thông tin
Thông tin xuất bản

ChemBioChem

Tập 17 Số 7

570-575

Thông tin tác giả